1. OFR-8 Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines
- Author
-
J. R. F. Cummings, Richard Pollok, Tariq Ahmad, Claire Bewshea, Ajay Verma, Shaji Sebastian, Christopher A. Lamb, Simeng Lin, Jonathan Macdonald, Nick Powell, Shameer Mehta, Goodhand, Timothy J. McDonald, Philip J Smith, Klaartje Kok, D Chee, Nikolaos Kamperidis, Benjamin Hamilton, Rachel Nice, Tim Raine, Neil Chanchlani, Charlie W. Lees, Nicholas A. Kennedy, Peter M. Irving, and Aileen Fraser
- Subjects
2019-20 coronavirus outbreak ,business.industry ,Immunogenicity ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,fungi ,Virology ,Infliximab ,body regions ,Vaccination ,medicine ,In patient ,Dosing ,Seroconversion ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
OFR-8 Figure 1ConclusionsInfliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.
- Published
- 2021
- Full Text
- View/download PDF